1. Home
  2. GRBK vs FOLD Comparison

GRBK vs FOLD Comparison

Compare GRBK & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRBK
  • FOLD
  • Stock Information
  • Founded
  • GRBK 2006
  • FOLD 2002
  • Country
  • GRBK United States
  • FOLD United States
  • Employees
  • GRBK N/A
  • FOLD N/A
  • Industry
  • GRBK Homebuilding
  • FOLD Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRBK Consumer Discretionary
  • FOLD Health Care
  • Exchange
  • GRBK Nasdaq
  • FOLD Nasdaq
  • Market Cap
  • GRBK 2.4B
  • FOLD 2.9B
  • IPO Year
  • GRBK N/A
  • FOLD 2007
  • Fundamental
  • Price
  • GRBK $57.55
  • FOLD $7.35
  • Analyst Decision
  • GRBK Hold
  • FOLD Strong Buy
  • Analyst Count
  • GRBK 3
  • FOLD 9
  • Target Price
  • GRBK $65.50
  • FOLD $17.00
  • AVG Volume (30 Days)
  • GRBK 319.7K
  • FOLD 4.0M
  • Earning Date
  • GRBK 04-30-2025
  • FOLD 05-01-2025
  • Dividend Yield
  • GRBK N/A
  • FOLD N/A
  • EPS Growth
  • GRBK 37.62
  • FOLD N/A
  • EPS
  • GRBK 8.45
  • FOLD N/A
  • Revenue
  • GRBK $2,098,943,000.00
  • FOLD $528,294,999.00
  • Revenue This Year
  • GRBK $5.34
  • FOLD $21.83
  • Revenue Next Year
  • GRBK $7.55
  • FOLD $22.16
  • P/E Ratio
  • GRBK $6.72
  • FOLD N/A
  • Revenue Growth
  • GRBK 18.07
  • FOLD 32.29
  • 52 Week Low
  • GRBK $50.57
  • FOLD $6.20
  • 52 Week High
  • GRBK $84.66
  • FOLD $12.65
  • Technical
  • Relative Strength Index (RSI)
  • GRBK 51.11
  • FOLD 46.28
  • Support Level
  • GRBK $56.51
  • FOLD $6.63
  • Resistance Level
  • GRBK $59.88
  • FOLD $7.25
  • Average True Range (ATR)
  • GRBK 2.74
  • FOLD 0.40
  • MACD
  • GRBK 0.30
  • FOLD 0.11
  • Stochastic Oscillator
  • GRBK 74.92
  • FOLD 85.82

About GRBK Green Brick Partners Inc.

Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgage and title.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: